NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA
Hoersholm; February 24, 2016 – Medical Prognosis Institute A/S (MPI.CO) (Denmark og Phoenix, AZ, USA) announced today that registration of capital increase is completed.
With reference to company announcement published on February 19th 2016 we are pleased to announce that the capital increase of 64,345 new shares with a nominal value of DKK 1 each was registered with the Danish Business Authority today.
Following registration of the 64,345 new shares with a nominal value of DKK 1 each, the nominal value of the share capital of Medical Prognosis Institute A/S amounts to DKK 1,164,115 divided into 1,164,115 shares with a nominal value of DKK 1 each.
Each share of nominally DKK 1 carries one vote at general meetings in the company.
The new shares is to be traded on First North Copenhagen under the same ISIN code as the company’s existing shares with expected first day of trading on March 1st 2016.
About MPI’s multiple biomarker called Drug Response Predictor – DRP(TM)
MPI’s lead product, the DRP(TM) diagnostic platform, is a tool to develop tumor-derived gene signatures that may predict which cancer patients are highly likely responders to a given anticancer product. The DRP(TM) has been tested in 37 trials, where 29 trials showed that drug-specific DRP(TM) Biomarkers could predict which patients had a positive effect of the treatment. The DRP(TM) platform has also been externally validated and published in collaboration with leading statisticians at the MD Anderson Cancer Center. The DRP(TM) method can be used to design the Clinical Development Plan, i.e. to select which indications are relevant for a given anticancer drug. Further to and in addition to this, individual patients’ gene patterns can be analyzed as part of a screening procedure for a clinical trial to ensure inclusion of those patients who have a high likelihood of response to the drug. This DRP(TM) method builds on the comparison of sensitive and resistant human cancer cell lines including genomic information from cell lines combined with clinical tumor biology and clinical correlates in a systems biology network. MicroRNA is used on certain products whereas the messenger RNA is more broadly useable and more validated. The DRP(TM) platform can be used in all cancer types and has been patented for more than 60 anticancer drugs in the US.
Medical Prognosis Institute advances personalized medicine by partnering with cancer drug developers to apply its DRP(TM) diagnostic platform to streamline and de-risk clinical trials and drug development via biomarker optimization, patient stratification, and development of companion diagnostics.
For further information, please contact
CEO, Peter Buhl Jensen, Adjunct Professor, MD, Ph.d.
Phone: +45 21 60 89 22
Certified Advisor: Carsten Yde Hemme, PricewaterhouseCoopers, Strandvejen 44, 2900 Hellerup, Denmark